- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT06888687
Porównanie wsparcia dietetyki z ciągłym monitorowaniem glukozy u osób z cukrzycą typu 2. (CARE-T2D)
Ciągłe monitorowanie glukozy wspomagane odległe dietetyka e-zdrowia w celu wzmocnienia osobników z cukrzycą typu 2
A parallel, single-blinded, randomised clinical trial conducted remotely across Australia from the Mary MacKillop Institute for Health Research (MMIHR, Australian Catholic University) for individuals with type 2 diabetes, by researchers from Australian Catholic University, University of Adelaide, University of Queensland, University of Wollongong, Monash University, Monash Partners, Deakin University, La Trobe University and Melbourne University.
Przegląd badań
Status
Interwencja / Leczenie
Szczegółowy opis
In a parallel groups design, a total of 156 individuals will be recruited. After baseline pathology (HbA1c), blinded (Libre Pro iQ) continuous glucose monitoring (CGM) data and questionnaires (via REDCap) have been collected, participants will be randomised into one of two groups (DIET, dietetic support only; CGMD, CGM plus dietetic support). All participants will receive four (4) dietetic consults via telehealth at weeks 2, 6, 10 and 16, the content of which will be related to the randomised condition. Measurements will be repeated at 3 and 6 months from baseline to assess the changes in primary and secondary outcomes.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Victoria
-
Melbourne, Victoria, Australia, 3065
- Australian Catholic University
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Aged 18+ years
- Reside anywhere in Australia and have a postal address
- Confirmed T2D diagnosis by a GP/endocrinologist
- Current HbA1c of ≥7.0%
- Have a smartphone and able to independently use it
Exclusion Criteria:
- Under the age of 18 years
- Use of insulin therapy (within the last three months) or medications which interfere with blood glucose levels (i.e. steroids)
- Use of CGM within the last six months
- Eating Disorder Examination Questionnaire (EDE-Q) global score >2.8 OR global score > or equal to 1.52, with sum of Q14-18 > or equal to 4
- Currently having ongoing consultations with an APD or have had a consult with an APD (within last three months)
- Not weight stable (>5 kg change over last three months)
- Severe hypoglycaemic event (i.e. requiring assistance) within last six months
- Change of antihyperglcyaemic medications within last three months
- Women who are pregnant or breastfeeding (within 24 weeks)
- History of psychotic disorder, or current diagnosis of other major psychiatric illness (e.g. mood disorder, eating disorder, substance use disorder)
- History of blood disorders (including but, not limited to, anemia and thalassemia) that impact the primary outcome (HbA1c)
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Aktywny komparator: Dietetic support only
This group is designed to act as a comparator using 'standard care' in dietetics practice. Dietary advice provided to this participant group will be performed by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence. |
Dietary advice will be provided by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence. |
|
Eksperymentalny: CGM plus dietetic support
The CGM plus dietetic support group will be provided 'standard care' dietetic support alongside the use, and interpretation of, the CGM data collected to assist in the understanding of dietary modifications on glucose management. As per the DIET group, dietary advice provided to this participant group will be performed by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence. The CGM data collected via LibreLink will be used by both the participant and the dietitian to inform dietary modifications. |
Dietary advice will be provided by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence. Abbott FreeStyle Libre 2+ CGM sensors will be used to provide feedback on interstitial glucose concentrations over 15 day periods per sensor. Nine sensors will be provided for the 6-month period, for 3 months of continuous use and 3 months of intermittent (2 weeks on - 2 weeks off) use. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
HbA1c
Ramy czasowe: baseline, 6 months
|
Glycated haemoglobin concentration |
baseline, 6 months
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
HbA1c
Ramy czasowe: 3 months
|
Glycated haemoglobin concentration |
3 months
|
|
24 h assessment of glycaemia
Ramy czasowe: baseline, 6 months
|
24 h glucose measures assessed by blinded CGM (including, but not limited to, time in range, CV) |
baseline, 6 months
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
CGM application and use
Ramy czasowe: From 0 to 26 weeks, per 2 week period of sensor use
|
number of days of CGM use and interaction with viewing CGM data (via LibreLink); CGMD group ony |
From 0 to 26 weeks, per 2 week period of sensor use
|
|
Per protocol analysis
Ramy czasowe: 6 months
|
Primary analysis of the primary outcome (0-6 months HbA1c) is going to be intention to treat. Therefore, secondary analysis of all other variables will be a per-protocol (PP) analysis. Inclusion in PP analysis will be defined by: 1. Attendance at ≥3 dietetic consults, within ±10 days of the designated 2-, 6-, 10- and 16-week time points. |
6 months
|
|
Dietary intake
Ramy czasowe: baseline, 3 months, 6 months
|
energy and macronutrient composition calculated from food records |
baseline, 3 months, 6 months
|
|
Fasting blood glucose
Ramy czasowe: baseline, 3 months, 6 months
|
fasting blood glucose concentrations |
baseline, 3 months, 6 months
|
|
Adherence
Ramy czasowe: baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 18 weeks, 20 weeks, 26 weeks
|
measures of adherence assessed by self-report (questionnaire) |
baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 18 weeks, 20 weeks, 26 weeks
|
|
hs-CRP
Ramy czasowe: baseline, 3 months, 6 months
|
fasting high sensitive C-Peptide concentrations |
baseline, 3 months, 6 months
|
|
Fasting cholesterol
Ramy czasowe: baseline, 3 months, 6 months
|
Fasting cholesterol concentrations (total, HDL and LDL) |
baseline, 3 months, 6 months
|
|
Fasting lipid concentration
Ramy czasowe: baseline, 3 months, 6 months
|
fasting triglyceride concentrations |
baseline, 3 months, 6 months
|
|
Medication effect score (MES)
Ramy czasowe: baseline, 6 months
|
Medication effect score for antihyperglycemic medications |
baseline, 6 months
|
|
Participant experience
Ramy czasowe: 6 months
|
Qualitative semi-structured interviews |
6 months
|
|
Physical activity
Ramy czasowe: baseline, 3 months, 6 months
|
Self-reported questionnaire (International Physical Activity Questionnaire (IPAQ) - Long Form) |
baseline, 3 months, 6 months
|
|
Sleep quality and quantity
Ramy czasowe: baseline, 3 months, 6 months
|
Self-reported questionnaire (Pittsburgh Sleep Quality Index (PSQI)) |
baseline, 3 months, 6 months
|
|
Eating behaviours
Ramy czasowe: baseline, 3 months, 6 months
|
Self-reported questionnaire (Eating Disorders Examination Questionnaire (EDEQ)) |
baseline, 3 months, 6 months
|
|
Health literacy
Ramy czasowe: baseline, 3 months, 6 months
|
self-reported questionnaire (Health Literacy Questionnaire (HLQ)) |
baseline, 3 months, 6 months
|
|
Dietary quality
Ramy czasowe: baseline, 3 months, 6 months
|
Assessed using the Healthy Eating Index For Australian adults (HEIFA) |
baseline, 3 months, 6 months
|
|
Diabetes self-management
Ramy czasowe: baseline, 3 months, 6 months
|
Self-reported questionnaire (Diabetes Self-Management Questionnaire (DSMQ-R)) |
baseline, 3 months, 6 months
|
|
Diabetes distress
Ramy czasowe: baseline, 3 months, 6 months
|
Self-reported questionnaire (Type 2 Diabetes Distress Assessment Scale (T2DDAS)) |
baseline, 3 months, 6 months
|
|
Overall well-being
Ramy czasowe: baseline, 3 months, 6 months
|
Self-reported questionnaire (WHO-5) |
baseline, 3 months, 6 months
|
|
Diabetes-specific well-being
Ramy czasowe: baseline, 3 months, 6 months
|
Self-reported questionnaire (DAWN Impact of Diabetes Profile (DIDP-7)) |
baseline, 3 months, 6 months
|
|
Treatment satisfaction
Ramy czasowe: baseline, 3 months, 6 months
|
self-reported questionnaire (Diabetes Treatment Satisfaction Questionnaire (DTSQs (status) and DTSQc (change))) |
baseline, 3 months, 6 months
|
Współpracownicy i badacze
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby układu hormonalnego
- Choroby metaboliczne
- Zaburzenia metabolizmu glukozy
- Cukrzyca
- Choroby żywieniowe i metaboliczne
- Cukrzyca typu 2
- Techniki śledcze
- Techniki laboratoryjne kliniczne
- Techniki i procedury diagnostyczne
- Diagnoza
- Analiza chemiczna krwi
- Testy chemii klinicznej
- Techniki diagnostyczne, hormonalne
- Monitorowanie, fizjologiczne
- Ciągłe monitorowanie glukozy
Inne numery identyfikacyjne badania
- 2024-3690HC
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
The data that support the findings of this study will be available from the corresponding author for a period of 36 months from publication, upon reasonable request for academic use. The data will not be made publicly available, as it contains information that could compromise research participant consent.
Kryteria dostępu do udostępniania IPD
Reasonable requests of data for academic use will be considered. Requests can be made to the corresponding author of the publication. Data will not be made publicly available as it contains information that could compromise research participant consent.
Typ informacji pomocniczych dotyczących udostępniania IPD
- PROTOKÓŁ BADANIA
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .